Meldonium: Optimize Cellular Energy and Ischemic Protection
| Product dosage: 250mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 20 | $2.50 | $50.04 (0%) | 🛒 Add to cart |
| 30 | $2.30 | $75.07 $69.06 (8%) | 🛒 Add to cart |
| 60 | $2.00 | $150.13 $120.11 (20%) | 🛒 Add to cart |
| 90 | $1.50 | $225.20 $135.12 (40%) | 🛒 Add to cart |
| 120 | $1.20 | $300.26 $144.13 (52%) | 🛒 Add to cart |
| 180 | $0.90 | $450.40 $162.14 (64%) | 🛒 Add to cart |
| 270 | $0.75 | $675.60 $203.18 (70%) | 🛒 Add to cart |
| 360 | $0.60
Best per pill | $900.79 $216.19 (76%) | 🛒 Add to cart |
| Product dosage: 500mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 10 | $4.00 | $40.04 (0%) | 🛒 Add to cart |
| 20 | $3.60 | $80.07 $72.06 (10%) | 🛒 Add to cart |
| 30 | $3.20 | $120.11 $96.08 (20%) | 🛒 Add to cart |
| 60 | $2.80 | $240.21 $168.15 (30%) | 🛒 Add to cart |
| 90 | $2.00 | $360.32 $180.16 (50%) | 🛒 Add to cart |
| 120 | $1.60 | $480.42 $192.17 (60%) | 🛒 Add to cart |
| 180 | $1.20 | $720.64 $216.19 (70%) | 🛒 Add to cart |
| 270 | $1.00 | $1080.95 $270.24 (75%) | 🛒 Add to cart |
| 360 | $0.90
Best per pill | $1441.27 $324.29 (77%) | 🛒 Add to cart |
Synonyms | |||
Meldonium is a cardioprotective and anti-ischemic agent designed to enhance cellular metabolism under conditions of stress. Its primary mechanism of action involves the modulation of carnitine biosynthesis, shifting energy production to a more efficient and oxygen-sparing pathway. This makes it a valuable therapeutic option for managing various conditions characterized by insufficient oxygen supply to tissues. It is a prescription medication that requires careful patient evaluation and monitoring.
Features
- Active Pharmaceutical Ingredient: Meldonium dihydrate
- Pharmacotherapeutic Group: Other cardiac preparations, ATC code: C01EB22
- Standard available dosage forms: 250 mg and 500 mg capsules for oral administration
- Mechanism: Inhibits gamma-butyrobetaine hydroxylase, reducing the synthesis of L-carnitine
- Bioavailability: High, with rapid absorption following oral administration
- Half-life: Approximately 3-6 hours
- Excretion: Primarily renal
Benefits
- Enhances myocardial tolerance to ischemia by optimizing cellular energy metabolism and reducing the accumulation of toxic metabolites.
- Improves physical capacity and functional performance in patients with chronic heart failure and reduced exercise tolerance.
- Supports neurological recovery and function in cases of acute and chronic cerebrovascular insufficiency.
- Provides a protective effect on retinal and choroidal tissues in patients with vascular ocular disorders.
- Promotes more efficient glucose utilization, which is particularly beneficial under hypoxic conditions.
Common use
Meldonium is clinically indicated for the treatment of adults in a range of cardiovascular and cerebrovascular conditions. Its primary use is in the management of stable angina pectoris and chronic heart failure (NYHA Class I-III) as part of a combination therapy, where it aids in improving exercise capacity and reducing the frequency of anginal attacks. It is also prescribed for the functional recovery following cerebrovascular accidents, such as ischemic stroke, and in cases of reduced mental performance due to impaired cerebral blood flow. Off-label, it has been utilized in ophthalmology for vascular retinopathies and neuropathies.
Dosage and direction
The dosage of meldonium must be individualized based on the patient’s condition, severity of symptoms, and clinical response. The typical adult dosage ranges from 500 mg to 1000 mg per day, administered orally in divided doses (usually twice daily). For cardiovascular conditions, a common regimen is 250 mg to 500 mg taken twice daily. The course of treatment typically lasts 4 to 6 weeks, which may be repeated 2-3 times per year as determined by a physician. The medication is preferably taken before meals. It is crucial to adhere strictly to the prescribing physician’s instructions regarding dosage and duration. Self-adjustment of the dose is not recommended.
Precautions
Meldonium should be used with caution in patients with hepatic or renal impairment, as these conditions may alter its pharmacokinetics and necessitate dosage adjustments. Close monitoring of renal and hepatic function is advised during prolonged therapy. Due to its mechanism of influencing energy metabolism, its use in patients with severe metabolic disorders requires careful benefit-risk assessment. The effect on driving and operating machinery has not been systematically studied; however, patients should be cautious until they know how the drug affects them, particularly at the beginning of treatment. Use during pregnancy and lactation is not recommended unless the potential benefit justifies the potential risk to the fetus or infant, as sufficient clinical data is lacking.
Contraindications
Meldonium is contraindicated in patients with a known hypersensitivity to the active substance or any of the excipients in the formulation. Its use is also contraindicated in patients with severe hepatic insufficiency or end-stage renal disease due to the lack of data on safe use in these populations. It should not be used in children and adolescents under 18 years of age due to the absence of efficacy and safety data. Concomitant use with other drugs that significantly influence carnitine metabolism or have a pronounced vasodilatory effect may also be a contraindication, requiring thorough medical evaluation.
Possible side effect
Meldonium is generally well-tolerated; however, like all pharmacological agents, it can cause adverse reactions. The most commonly reported side effects are mild and transient. These may include:
- Cardiac disorders: Tachycardia, palpitations, blood pressure fluctuations (hypotension or hypertension).
- Nervous system disorders: Headache, agitation, emotional lability, sleep disturbances (insomnia or drowsiness).
- Gastrointestinal disorders: Dyspepsia, nausea, vomiting, diarrhea, or abdominal pain.
- Allergic reactions: Skin rash, pruritus, urticaria, erythema.
- Other: General weakness, a feeling of pressure in the chest, eosinophilia. Most of these effects are dose-dependent and often subside with continued treatment or dose reduction. Patients should report any persistent or severe side effects to their physician.
Drug interaction
The potential for pharmacokinetic interactions with meldonium is considered low, as it is not a significant inhibitor or inducer of major cytochrome P450 enzymes. However, pharmacodynamic interactions are possible. Concomitant administration with other antianginal drugs (e.g., nitrates, beta-blockers, calcium channel blockers) may lead to an additive hypotensive effect, requiring blood pressure monitoring. Caution is advised when using it with other drugs that affect heart rate. Concurrent use with supplements containing high doses of L-carnitine may theoretically reduce the efficacy of meldonium, as their mechanisms are antagonistic. A comprehensive review of the patient’s complete medication list is essential before initiation.
Missed dose
If a dose is missed, it should be taken as soon as it is remembered. However, if it is almost time for the next scheduled dose, the missed dose should be skipped. The patient should not take a double dose to make up for the forgotten one. Maintaining a regular dosing schedule is important for achieving stable therapeutic levels. Patients should be advised to consult their physician or pharmacist if they are uncertain about what to do after a missed dose.
Overdose
Cases of meldonium overdose have been rarely reported. Based on its pharmacological profile, symptoms of significant overdose may be an extension of its known side effects and could include pronounced hypotension, tachycardia, headache, dizziness, general weakness, and nausea. There is no known specific antidote. Management of suspected overdose should consist of symptomatic and supportive care, including monitoring of vital signs and ECG. Gastric lavage or administration of activated charcoal may be considered if ingestion was recent. Treatment should be directed at maintaining cardiovascular stability.
Storage
Store the medication in its original packaging to protect it from light and moisture. The recommended storage temperature is below 25°C (77°F). Keep the container tightly closed. It must be stored out of the sight and reach of children and pets. Do not use the medicine after the expiration date printed on the packaging. Do not dispose of unused medication via wastewater or household waste; consult a pharmacist on the proper disposal method to ensure environmental protection.
Disclaimer
This information is provided for educational and informational purposes only and does not constitute medical advice. It is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition or before starting any new treatment. Never disregard professional medical advice or delay in seeking it because of something you have read in this document. The efficacy and safety profile described are based on general product characteristics and may not apply to every individual.
Reviews
- “As a cardiologist, I have incorporated meldonium into the treatment regimen for select patients with chronic ischemic heart disease and Class II heart failure. The most notable outcome is the subjective and objective improvement in exercise tolerance, allowing patients to engage in physical rehabilitation with less dyspnea and fatigue. It serves as a useful adjunct to standard therapy.” – Dr. Elena V., Cardiologist
- “Following a minor ischemic stroke, my neurologist prescribed a 6-week course. The brain fog and constant fatigue I experienced began to lift noticeably after the second week. My concentration improved, and I felt more like my old self. The treatment was well-tolerated with no side effects.” – Patient, M, 68
- “In our clinical practice, we find it particularly beneficial for elderly patients with multimorbidity, where it helps manage both cardiac and cerebrovascular insufficiency. It appears to improve quality of life metrics related to energy levels and cognitive function in this vulnerable population. More robust, long-term outcome studies would be welcome.” – Clinical Research Team, Geriatric Department
- “I was initially skeptical, but after a month of use for stable angina, the frequency of my nitroglycerin use decreased significantly. I can now walk longer distances without chest tightness. A very positive addition to my medication list.” – Patient, F, 72